{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-022718","form_type":"8-K","ticker":"ADIL","cik":"0001513525","company_name":"ADIAL PHARMACEUTICALS, INC.","filed_at":"2026-03-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.281788+00:00","generated_at":"2026-05-15T22:14:17.598627+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Adial signs exclusive AD04 collaboration framework with Molteni for Europe; potential $60M in milestones and royalties","bullets":["Collaboration framework with Molteni Farmaceutici for exclusive AD04 commercialization in Europe; definitive agreement pending.","Total potential aggregate value from royalties (high single to low double digits) and milestones estimated at nearly $60M.","Molteni granted exclusivity for due diligence; upfront and milestone payments expected upon final agreement.","AD04 is a genotype-driven Alcohol Use Disorder therapy; company also advancing US partner discussions.","Special meeting on Feb 26 lacked quorum; company must call new meeting every 90 days until warrant approval."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-022718","json":"https://secwatch.observer/filing/0001213900-26-022718.json","markdown":"https://secwatch.observer/filing/0001213900-26-022718.md","text":"https://secwatch.observer/filing/0001213900-26-022718.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1513525/000121390026022718/0001213900-26-022718-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1513525/000121390026022718/ea0279472-8k_adial.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T22:14:17.598627+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}